PHOENIX, May 31, 2023
/PRNewswire/ -- Creative Medical Technology Holdings, Inc.
("Creative Medical Technology" or the "Company") (NASDAQ:
CELZ), a biotechnology company focused on a regenerative
approach to immunotherapy, endocrinology, urology, gynecology, and
orthopedics, today announced that it has received confirmation that
Greenstone Biosciences Inc. in Palo Alto,
CA has successfully developed a human induced pluripotent
stem cell (iPSC) pipeline for the Company's
ImmCelz® platform.
In June 2022, the Company
announced its collaboration with Greenstone Biosciences Inc. on
this project, called the iPScelz™ program, to enable the
Company to increase its scalability for the ImmCelz®
Immunotherapy Platform at a lower cost and continue its drug
discovery program using artificial intelligence.
Dr. Joseph C. Wu, co-founder of
Greenstone Biosciences, remarked, "This milestone sets the
foundation for a continued collaboration that translates our
expertise in iPSC technology to accelerate therapies that improve
patient care – fast-tracking bench to bedside." Dr. Wu is the
Director of the Stanford Cardiovascular Institute and the Simon H.
Stertzer, MD, Professor of Medicine & Radiology at Stanford
University.
Timothy Warbington, President and
CEO of the Company, commented, "We are excited that our work with
Dr. Joseph Wu and the Greenstone team at Alexandria Center for Life
Sciences (ACLS) has resulted in very rapid and positive results
that help accelerate our next generation pipeline. Greenstone's extensive experience in the
development of iPSC technologies brings independent validation to
the iPScelz™ program. We estimate that the development of this cell
line will save the Company two to three years in research and
development time along with associated expenses. The final iPScelz™
results in a viral-free cell line which has great potential for
differentiation into therapeutic biologics both for the cellular
and cell-free programs along with targeted drug discovery."
About ImmCelz®
ImmCelz®, which
is protected by trade secrets and published U.S. patents, utilizes
adult stem cells derived from qualified donors to endow specific
properties to the patient's immune cells. After the patient's
harvested cells are incubated with the Company's cell-free
reprogramming "cocktail", the cells are re-injected back into the
patient. These "supercharged" cells subsequently "educate"
other cells of the immune system to stop attacking the body, while
preserving the ability to attack foreign pathogens.
About Greenstone Biosciences
Greenstone Biosciences,
Inc. (Palo Alto, CA) is a
biotechnology company co-founded by Joseph
C. Wu, MD, PhD and Jade Chao,
JD, MPH. The biotech company specializes in clinical genomics, iPSC
technology, AI/ML, and drug development. Greenstone has extensive knowledge and
expertise in generating patient-derived human iPSCs and
differentiate to numerous cell types for disease modeling and drug
discovery. For further information, please visit
www.greenstonebio.com.
About Creative Medical Technology Holdings
Creative
Medical Technology Holdings, Inc. is a biotechnology company
dedicated to the advancement of identifying and translating novel
biological therapeutics in the fields of immunotherapy,
endocrinology, urology, gynecology, and orthopedics and is traded
on NASDAQ under the ticker symbol CELZ. For further information
about the Company, please
visit www.creativemedicaltechnology.com.
Forward Looking Statements
This news release may
contain forward-looking statements including but not limited to
comments regarding the timing and content of upcoming clinical
trials and laboratory results, marketing efforts, funding, etc.
Forward-looking statements address future events and conditions
and, therefore, involve inherent risks and uncertainties. Actual
results may differ materially from those currently anticipated in
such statements. See the periodic and other reports filed by
Creative Medical Technology Holdings, Inc. with the Securities and
Exchange Commission and available on the Commission's website at
www.sec.gov.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/creative-medical-technology-holdings-announces-successful-completion-of-the-first-phase-of-its-program-with-greenstone-biosciences-inc-to-develop-next-generation-ipsc-pipeline-for-immcelz-immunotherapy-platform-301837755.html
SOURCE Creative Medical Technology Holdings, Inc.